- Home
- DTIL
as 05-09-2025 4:00pm EST
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Upcoming Earnings Alert:
Get ready for potential market movements as Precision BioSciences Inc. DTIL prepares to release earnings report on 15 May 2025.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 56.2M | IPO Year: | 2019 |
| Target Price: | $47.00 | AVG Volume (30 days): | 157.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.61 - $13.44 | Next Earning Date: | 05-15-2025 |
| Revenue: | $68,696,000 | Revenue Growth: | 40.98% |
| Revenue Growth (this year): | -67.38% | Revenue Growth (next year): | 30.20% |
Stock Insider Trading Activity of Precision BioSciences Inc. (DTIL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Buehler Kevin | DTIL | Director | Mar 26 '25 | Buy | $4.67 | 4,523 | $21,122.41 | 13,235 | |
| Brown Melinda | DTIL | Director | Mar 26 '25 | Buy | $4.75 | 1,839 | $8,735.25 | 9,057 | |
| Germano Geno J | DTIL | Director | Mar 25 '25 | Buy | $5.30 | 3,250 | $17,225.00 | 11,057 | |
| Amoroso Michael | DTIL | President and CEO | Mar 21 '25 | Sell | $5.56 | 964 | $5,359.84 | 109,540 | |
| Scimeca Dario | DTIL | General Counsel and Secretary | Mar 3 '25 | Sell | $4.91 | 272 | $1,335.52 | 25,000 | |
| SMITH J. JEFFERSON | DTIL | Chief Research Officer | Mar 3 '25 | Sell | $4.91 | 154 | $756.14 | 87,805 |
Latest Precision BioSciences Inc. News
DTIL Breaking Stock News: Dive into DTIL Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025
Business Wire
5 days ago
Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)
Business Wire
11 days ago
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Business Wire
13 days ago
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zacks
a month ago
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up
MT Newswires
a month ago
Precision BioSciences Gets FDA Fast Track Label for PBGENE-HBV
Business Wire
a month ago
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
TipRanks
a month ago
Biotech stocks slide as Marks resignation seen being negative for sector
Compare DTIL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DTIL Precision BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.